Latest Period
Q1 2026
Security Snapshot
C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC) Institutional Ownership
CUSIP: 12529R107
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
122
Shares (Excl. Options)
84,491,097
Price
$2.63
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- CCCC on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 84,491,097
- Total 13F value
- $221,300,312
- Portfolio coverage rank
- 0%
- Share change
- +4,472,457
- Value change
- +$11,954,068
- Number of holders
- 122
- Shares outstanding
- 111,000,000
- SEC-reported price per share
- $2.92
- Insider filing price
- $2.92
Latest holder snapshot
5 signals
Issuer context
Who this page is about.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CCCC - C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 12529R107.
- 122 institutions reported positions in Q1 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 101 to 122 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $152,468,758 to $221,300,312.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 122 institutions filings for Q1 2026.
Security key
12529R107
Latest holder period
Q1 2026
13F holders
122
13D/G owners
11
CIK / CUSIP context first
Open Q1 2026 holders
CCCC full holder history
C4 Therapeutics, Inc. SEC filings
C4 Therapeutics, Inc. company facts
C4 Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 12529R107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
CCCC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sirenia Capital Management LP | 9.9% | $59,702,700 | 23,505,000 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Soleus Capital Master Fund, L.P. | 10% | $19,791,153 | 10,361,860 | Soleus Capital Master Fund, L.P. | 31 Dec 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $20,959,588 | +$20,959,588 | 9,441,256 | RA Capital Management, L.P. | 17 Oct 2025 | ||
| MORGAN STANLEY | 9.3% | +37% | $17,140,705 | +$8,067,473 | 8,974,191 | +89% | Morgan Stanley | 31 Dec 2025 |
| Lynx1 Capital Management LP | 7.3% | $13,557,434 | 7,098,133 | Lynx1 Capital Management LP | 31 Dec 2025 | |||
| Bain Capital Life Sciences Fund II, L.P. | 6.2% | $13,453,200 | 6,060,000 | BCLS II Equity Opportunities, LP | 17 Oct 2025 | |||
| Squadron Capital Management LLC | 5% | $16,206,000 | 5,550,000 | Squadron Master Fund LP | 12 May 2026 | |||
| WASATCH ADVISORS LP | 6.8% | -34% | $10,773,085 | -$5,817,712 | 4,852,741 | -35% | Wasatch Advisors LP | 30 Sep 2025 |
| BlackRock, Inc. | 2.5% | $2,513,362 | 1,756,613 | BlackRock, Inc. | 30 Jun 2025 | |||
| ORBIMED ADVISORS LLC | 1% | -80% | $1,687,550 | -$5,127,991 | 883,534 | -75% | OrbiMed Capital LLC | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 0.2% | -97% | $429,504 | -$57,095,520 | 169,096 | -99% | Point72 Asset Management, L.P. | 31 Mar 2026 |
As of 31 Mar 2026, 122 institutional investors reported holding 84,491,097 shares of C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC). This represents 76% of the company’s total 111,000,000 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
67%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 8.2% | 9,072,400 | +1% | 0% | $23,860,411 |
| RA CAPITAL MANAGEMENT, L.P. | 7.2% | 8,000,000 | 0% | 0.22% | $21,040,000 |
| Bain Capital Life Sciences Investors, LLC | 6.5% | 7,171,910 | 0% | 1.7% | $18,862,123 |
| Lynx1 Capital Management LP | 6.3% | 6,998,902 | -1.4% | 2.9% | $18,407,112 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 3,861,852 | 0% | 0% | $10,156,671 |
| Soleus Capital Management, L.P. | 3.4% | 3,803,942 | 0% | 0.41% | $10,004,367 |
| JPMORGAN CHASE & CO | 2.9% | 3,223,054 | +54115% | 0% | $7,574,177 |
| TWO SIGMA INVESTMENTS, LP | 2.7% | 3,035,634 | +101% | 0.01% | $7,983,717 |
| WASATCH ADVISORS LP | 2.7% | 2,961,761 | -32% | 0.05% | $7,789,431 |
| CITADEL ADVISORS LLC | 2.3% | 2,511,015 | +461% | 0% | $6,603,969 |
| RENAISSANCE TECHNOLOGIES LLC | 2.2% | 2,461,815 | +54% | 0.01% | $6,474,573 |
| GOLDMAN SACHS GROUP INC | 2.2% | 2,387,378 | +119% | 0% | $6,278,804 |
| BANK OF AMERICA CORP /DE/ | 2.1% | 2,359,241 | -1.2% | 0% | $6,204,805 |
| Squadron Capital Management LLC | 2% | 2,250,000 | 2.4% | $5,917,500 | |
| BlackRock, Inc. | 1.8% | 2,048,526 | +4% | 0% | $5,387,622 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.7% | 1,911,785 | -4.1% | 0.59% | $5,027,995 |
| ACADIAN ASSET MANAGEMENT LLC | 1.7% | 1,890,914 | +188% | 0.01% | $4,968,000 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 1,393,342 | +17% | 0% | $3,664,489 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.2% | 1,286,840 | -28% | 0% | $3,384,389 |
| JANE STREET GROUP, LLC | 1.1% | 1,246,896 | +43% | 0% | $3,279,336 |
| D. E. Shaw & Co., Inc. | 0.96% | 1,060,331 | +1905% | 0% | $2,788,670 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.86% | 951,043 | -3.8% | 0% | $2,502,399 |
| WELLS FARGO & COMPANY/MN | 0.78% | 867,911 | +7.2% | 0% | $2,282,606 |
| ORBIMED ADVISORS LLC | 0.77% | 856,353 | -39% | 0.05% | $2,252,208 |
| CONGRESS ASSET MANAGEMENT CO | 0.75% | 830,624 | 0.02% | $2,184,541 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
22
Latest
Q1 2026
Rows shown
1-22 of 22
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 84,491,097 | $221,300,312 | +$11,954,068 | $2.63 | 122 |
| 2025 Q4 | 79,828,313 | $152,468,758 | +$51,887,612 | $1.91 | 101 |
| 2025 Q3 | 52,538,995 | $116,636,299 | -$3,450,925 | $2.22 | 96 |
| 2025 Q2 | 54,715,914 | $78,242,864 | -$14,672,718 | $1.43 | 102 |
| 2025 Q1 | 64,100,740 | $102,562,013 | -$12,577,745 | $1.60 | 113 |
| 2024 Q4 | 64,400,415 | $231,841,449 | -$9,805,080 | $3.60 | 113 |
| 2024 Q3 | 64,180,724 | $365,858,667 | +$21,073,945 | $5.70 | 118 |
| 2024 Q2 | 60,887,928 | $281,302,982 | +$5,545,189 | $4.62 | 114 |
| 2024 Q1 | 58,201,499 | $475,505,218 | +$93,890,692 | $8.17 | 104 |
| 2023 Q4 | 47,001,017 | $265,585,658 | +$85,422,229 | $5.65 | 91 |
| 2023 Q3 | 34,671,251 | $64,488,483 | -$134,435 | $1.86 | 82 |
| 2023 Q2 | 34,220,399 | $94,120,957 | -$9,383,233 | $2.75 | 96 |
| 2023 Q1 | 37,418,446 | $117,492,869 | -$15,156,032 | $3.14 | 117 |
| 2022 Q4 | 39,224,213 | $231,404,815 | -$9,766,681 | $5.90 | 113 |
| 2022 Q3 | 39,456,577 | $346,000,579 | -$2,524,371 | $8.77 | 115 |
| 2022 Q2 | 39,425,650 | $297,247,580 | -$39,977,861 | $7.54 | 111 |
| 2022 Q1 | 37,306,180 | $904,604,832 | +$6,530,479 | $24.26 | 120 |
| 2021 Q4 | 35,893,940 | $1,154,835,979 | +$16,687,200 | $32.20 | 115 |
| 2021 Q3 | 34,491,766 | $1,542,710,693 | +$110,759,163 | $44.68 | 110 |
| 2021 Q2 | 31,945,852 | $1,209,520,921 | +$259,679,873 | $37.84 | 106 |
| 2021 Q1 | 25,097,387 | $926,788,055 | +$90,401,887 | $36.99 | 83 |
| 2020 Q4 | 22,706,689 | $743,535,975 | +$718,564,975 | $33.13 | 75 |